• Immobilized Microalgae Extracts Enhance Antioxidant Packagin

  2026-06-05

  This study demonstrates that immobilizing Chlorella sp. in a silk fibroin–reinforced sodium alginate matrix nearly doubles antioxidant yield and biomass compared to suspension cultures. The resulting extracts, when incorporated into biodegradable films, significantly improve oxidative stability and food preservation, offering a sustainable approach to active packaging.

• YM 58483 (BTP2): Applied SOCE Inhibition in Fibrosis Models

  2026-06-05

  YM 58483 (BTP2) delivers highly selective SOCE inhibition, empowering immunology and fibrosis researchers to dissect calcium-dependent pathways with precision. Its proven effectiveness in modulating the ORAI2/JNK/NFAT1/TGF-β1 axis makes it a pivotal tool for modeling postirradiation tissue fibrosis and T cell-driven responses.

• Sinapine Disrupts Gαq-PLCβ3 Axis to Alleviate Cardiovascular

  2026-06-04

  This study identifies sinapine as a selective inhibitor that disrupts the Gαq-PLCβ3 interaction by targeting PLCβ3 EF hand domains, thereby ameliorating aldosteronism and hypertension in preclinical models. The work introduces a novel strategy for modulating the renin-angiotensin-aldosterone system (RAAS) with improved specificity and fewer side effects compared to conventional Gαq or pan-PLC inhibitors.

• BAPTA-AM: Cell-Permeable Calcium Chelator for Precision Assa

  2026-06-04

  BAPTA-AM stands out as a gold-standard tool for manipulating intracellular calcium dynamics in live-cell studies. Its cell-permeable design enables targeted regulation of calcium signaling, unlocking advanced apoptosis assays and high-fidelity neuroprotection models.

• Efficacy and Safety of Azilsartan Medoxomil in Hypertension:

  2026-06-03

  This systematic review and meta-analysis rigorously evaluates azilsartan medoxomil’s efficacy and safety for hypertension, including patients with diabetes. The findings position TAK 491 as one of the most effective angiotensin II receptor blockers for blood pressure reduction, with no increased risk of adverse events compared to controls.

• CBD Modulates Orofacial Inflammatory Pain via Multi-Domain M

  2026-06-03

  This study demonstrates that cannabidiol (CBD) effectively attenuates both the sensory and emotional components of orofacial inflammatory pain in murine models. By dissecting the peripheral and central pathways—including CB1 and CB2 receptor signaling—the research highlights CBD's translational potential for comprehensive pain management and supports the need for targeted molecular tools in pain mechanism studies.

• Verapamil HCl: L-Type Calcium Channel Blocker in Bone & Canc

  2026-06-02

  Verapamil HCl is a well-characterized L-type calcium channel blocker with robust solubility and validated efficacy in inhibiting calcium influx, thereby modulating cellular excitability and apoptosis. Its bench-to-model translational value spans from myeloma cell research to attenuation of arthritis inflammation and suppression of osteoporosis-related bone turnover, as supported by recent peer-reviewed studies.

• Otilonium Bromide: Antimuscarinic Agent for Cholinergic Rese

  2026-06-02

  Otilonium Bromide is a high-purity antimuscarinic agent used to inhibit acetylcholine receptors in neuroscience and smooth muscle research. Its robust solubility and validated specificity enable precise modulation of the cholinergic signaling pathway. This article details its biological rationale, documented mechanisms, application limits, and protocol integration.

• E-4031 and the Next Era of 3D Cardiac Electrophysiology

  2026-06-01

  Explore how E-4031, a gold-standard hERG potassium channel blocker, is redefining translational strategies in 3D cardiac electrophysiology research. This article unpacks mechanistic insights, protocol guidance, and the transformative impact of high-resolution 3D mapping platforms—empowering researchers to model arrhythmogenic risk with unprecedented fidelity.

• Vernakalant Hydrochloride: Unpacking PK/PD for Precision AF

  2026-06-01

  Explore Vernakalant Hydrochloride's pharmacokinetics and pharmacodynamics in depth, including its unique atrial-selective actions for rapid conversion of atrial fibrillation. This article reveals key insights for advanced assay design and clinical translation.

• Quercetin as a PI3K Inhibitor: Mechanistic Leverage for Tran

  2026-05-31

  This article provides a thought-leadership perspective for translational researchers on leveraging Quercetin, a potent PI3K inhibitor, in experimental workflows. Integrating recent mechanistic discoveries—particularly its dual action on apoptosis and ferroptosis—this piece bridges molecular insight with practical strategy, offering advanced guidance for those aiming to exploit Quercetin’s multi-targeted effects in cancer and liver disease models. The discussion highlights protocol considerations, competitive positioning, and strategic outlook, with evidence-based recommendations and contextual product insights from APExBIO.

• Multi-Omics Reveals ARID1A-Driven Resistance to Vemurafenib

  2026-05-30

  This study applies integrative multi-omics to dissect drug resistance networks in BRAF-mutant melanoma, identifying ARID1A loss as a key driver of sustained MAPK signaling and immune evasion under BRAF/MAPK inhibitor treatment. The findings highlight actionable resistance nodes and inform strategies for overcoming therapeutic failure in metastatic melanoma.

• 3D Electrophysiological Mapping of Cardiac Organoids with Sh

  2026-05-29

  This study introduces shell microelectrode arrays enabling true 3D, high-resolution electrophysiological mapping of cardiac organoids. The platform allows detailed analysis of conduction dynamics, arrhythmogenic risk, and pharmacological response—advancing the modeling of human cardiac disease and drug safety.

• Ellagic Acid in Cancer Biology: Protocols and Senolytic Inno

  2026-05-29

  Ellagic acid's selective ATP-competitive CK2 inhibition enables precise cancer biology and oxidative stress research. This article delivers actionable protocols, AI-driven assay enhancements, and troubleshooting guidance for advanced experimental workflows.

• hiPSC-Derived Intestinal Organoids Advance Pharmacokinetic S

  2026-05-28

  This paper presents a streamlined protocol to generate human pluripotent stem cell-derived intestinal organoids with robust self-renewal and differentiation potential. The resulting organoid-derived epithelial cells provide a more physiologically relevant in vitro model for pharmacokinetic research, particularly for studying drug absorption and metabolism in the human intestine.

11454 records 1/764 page Next 12345 下5页 Last page